CLINICAL AND FUNCTIONAL INDICATORS IN PATIENTS WITH PRIMARY GONARTHROSIS AFTER PHYSIOPHARMACOTHERAPY WITH TRANSDERMAL NON-STEROID ANTI-INFLAMMATORY DRUGS

Read full text Summarise with VIRAT
Authors: V.А. Drobyshev, L.A. Shpagina, Котова Ольга Сергеевна, С Г Абрамович, Lev Georgievich Agasarov, S.A. Karmanovskaya, Локтин Евгений Михайлович
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction. In the structure of diseases of the musculoskeletal system, one of the first places belongs to osteoarthritis (OA), which is one of the main reasons for limiting the functional capabilities of patients. In the updated national clinical guidelines “Gonarthrosis 2024”, the emphasis is placed on conservative therapy, including the use of physical rehabilitation methods, physiotherapeutic procedures, and the use of topical forms of non-steroidal anti-inflammatory drugs (NSAIDs). Aim of the research. To identify the effect of ultraphonophoresis of the topical form of tenoxicam-gel Artoxan on the severity of pain syndrome and clinical and functional parameters in patients with primary gonarthritis in the stage of subsiding exacerbation. Materials and methods. In an open observational prospective study, 45 men and women aged 35 to 65 years (average age 42.4±4.5 years) with Kellgren–Lawrence stage I-II knee osteoarthritis were examined, complaining of pain and limited mobility in the lower extremities, divided into 3 groups: in the 1st – the basic treatment complex was supplemented with ultraphonophoresis on the affected joints of the transdermal form (1% gel) of the nonsteroidal anti-inflammatory drug Artoxan (tenoxicam) from the group of the thienothiazine derivative oxycam; in the 2nd, placebo ultraphonophoresis procedures were performed; in the 3rd, basic treatment was supplemented with the application of Artoxan gel to pain areas for four weeks. In all groups, the severity of pain syndrome was assessed using the visual analog scale (VAS), and a standard ultrasound examination of the affected joints was performed at baseline and 4 weeks later. Results. According to the results of the study, the introduction of Artoxan gel into the periarticular tissues using ultrasound promotes a rapid pain-relieving effect, which was observed in patients in the first group by the third procedure, and differed from the initial values by 2.4 times by the seventh procedure, and by 3.9 times by the twelfth procedure. After a four-week treatment course, the pain, stiffness, and functional impairment scores in Group 1 patients decreased by 1.3 times, 1.25 times, and 1.2 times, respectively, while the total WOMAC score decreased by 1.2 times. By the end of the follow-up period, according to ultrasound examination, patients in the 1st group had a 1.6-fold decrease in joint effusion, a 1.4-fold decrease in joint space height, and a 1.4-fold decrease in the number of vessels per 1 cm2 of scan compared to the initial value. At the same time, the changes in the studied parameters in the comparison groups were smaller. Conclusion. Supplementing treatment regimens with ultraphonophoresis of Artoxan gel reduces the severity of pain and stiffness, and improves the condition of the articular surfaces in patients with primary gonarthrosis in the stage of subsiding exacerbation, which differs from the similar results in the placebo groups and the course of applying Artoxan gel to the affected joints.

Fields of Study & Subjects

Osteoarthritis Treatment and Mechanisms Musculoskeletal pain and rehabilitation Complementary and Alternative Medicine Studies

Publication details

Journal / source
Sibirskij medicinskij vestnik
Volume
10
Issue
1
Pages
20–26
Publication date
1 January 2026
Language
EN